Embargoed until: March 3, 2016, 7 a.m.

Evonik begins basic engineering for an additional methionine
plant in Singapore• Global increase in demand for DL-methionine in animalnutrition• Second fully backward-integrated plant planned inSingapore• Targeted annual capacity of 150,000 metric tons
Evonik Industries has started basic engineering for the constructionof a second world-scale production plant for the amino acid DLmethionine in Singapore. The plant complex, with a projectedannual production capacity of 150,000 metric tons, is expected tocome on stream in 2019. The Evonik committees have now
approved the basic engineering.

March 3, 2016
Contact Person Economic Press
Alexandra Boy
Deputy Head of Corporate Press
Phone +49 201 177-3167
Fax +49 201 177-3030
alexandra.boy@evonik.com
Contact Person Specialized Press
Dr. Jürgen Krauter
Vice President Communications/
Nutrition & Care
Phone +49 6181 59-6847
Fax +49 6181 59-76847
juergen.krauter@evonik.com

The decision is based on the continuing increase in the demand forsustainable animal nutrition. “We have supported the strong market
growth of DL-methionine over the years by timely and needs-driven
expansion of our production capacities, and we plan to continue
doing this,” says Klaus Engel, Chairman of the Executive Board ofEvonik. The specialty chemicals group markets DL-methionine
under the MetAMINO® brand name.
The new complex will be erected next to Evonik’s existingmethionine plant on Jurong Island, Singapore, which wascommissioned in late 2014. “Like our first methionine plant inSingapore, which went on stream on schedule, this project too isprogressing according to plan,” explains Reiner Beste, chairman ofthe Board of the Management of Evonik Nutrition & Care GmbH.
Singapore was once again selected as the site because Evonik canservice the Asian growth market particularly well from there. And
once again, in the new, fully backward-integrated production
complex, Evonik will produce all strategically important precursors
itself. “This guarantees high product quality as well as supplysecurity,” says Beste.

Page 1 of 3

Evonik Industries AG
Rellinghauser Straße 1-1145128 Essen
Phone +49 201 177-01
Fax+49 201 177-3475
www.evonik.de
Supervisory Board
Dr. Werner Müller, Chairman
Executive Board
Dr. Klaus Engel, Chairman
Dr. Ralph Sven KaufmannChristian Kullmann
Thomas Wessel
Ute Wolf
Registered Office: Essen
Register Court:
Essen Local Court
Commercial Registry B 19474
VAT no. DE 811160003

The specialty chemicals group is already producing DL-methionine
at world-scale plants in Antwerp (Belgium), Wesseling/Cologne(Germany), Mobile (Alabama, USA), and Singapore.
DL-methionine is an essential amino acid that must be supplied infeed. As a feed additive it contributes toward efficient, healthy, andecofriendly nutrition of agricultural livestock, particularly poultry
and pigs.
Population growth and rising standards of living are leading inmany regions of the world to an increase in meat consumption,
which in turn increases demand for methionine. The addition ofthis and other amino acids to animal feeds allows the raw protein
content to be significantly reduced. This reduces the burden on theenvironment by reducing resource consumption, the greenhouseeffect, and the potential for eutrophication and acidification.
Evonik translates over 60 years of experience in manufacturing
essential amino acids for animal nutrition into solutions that meetthe evolving needs of its customers in over one hundred countries.
As Evonik now expands its scope to innovative nutritional feed
additive solutions beyond amino acids, customers can count on
Evonik to take nutrient effectiveness ever further and keep
delivering value along with consistent quality. Around the planet,
Evonik products and services are and will continue to be key toproducing healthy, affordable food with fewer natural resources
and a smaller environmental footprint.

Page 2 of 3

Company information
Evonik, the creative industrial group from Germany, is one of the world leaders inspecialty chemicals, operating in the Nutrition & Care, Resource Efficiency andPerformance Materials segments. The company benefits from its innovative
prowess and integrated technology platforms. In 2015 more than 33,500
employees generated sales of around €13.5 billion and an operating profit(adjusted EBITDA) of about €2.47 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH andcontributes to fulfilling basic human needs. That includes applications foreveryday consumer goods as well as animal nutrition and health care. Thissegment employed about 7,000 employees, and generated sales of around€4.9 billion in 2015.
Disclaimer
In so far as forecasts or expectations are expressed in this press release or where
our statements concern the future, these forecasts, expectations or statements
may involve known or unknown risks and uncertainties. Actual results ordevelopments may vary, depending on changes in the operating environment.
Neither Evonik Industries AG nor its group companies assume an obligation to
update the forecasts, expectations or statements contained in this release.

Page 3 of 3